G&E Herbal Biotechnology Statistics
Total Valuation
G&E Herbal Biotechnology has a market cap or net worth of TWD 2.99 billion. The enterprise value is 2.67 billion.
Market Cap | 2.99B |
Enterprise Value | 2.67B |
Important Dates
The next estimated earnings date is Friday, November 8, 2024.
Earnings Date | Nov 8, 2024 |
Ex-Dividend Date | Aug 20, 2024 |
Share Statistics
G&E Herbal Biotechnology has 55.66 million shares outstanding. The number of shares has increased by 0.10% in one year.
Shares Outstanding | 55.66M |
Shares Change (YoY) | +0.10% |
Shares Change (QoQ) | -0.05% |
Owned by Insiders (%) | n/a |
Owned by Institutions (%) | n/a |
Float | n/a |
Valuation Ratios
The trailing PE ratio is 37.80.
PE Ratio | 37.80 |
Forward PE | n/a |
PS Ratio | 15.00 |
PB Ratio | 4.09 |
P/FCF Ratio | 23.12 |
PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 25.83, with an EV/FCF ratio of 20.63.
EV / Earnings | 31.82 |
EV / Sales | 12.63 |
EV / EBITDA | 25.83 |
EV / EBIT | 28.56 |
EV / FCF | 20.63 |
Financial Position
The company has a current ratio of 3.61, with a Debt / Equity ratio of 0.28.
Current Ratio | 3.61 |
Quick Ratio | 3.39 |
Debt / Equity | 0.28 |
Debt / EBITDA | 0.02 |
Debt / FCF | 0.02 |
Interest Coverage | 4,059.43 |
Financial Efficiency
Return on equity (ROE) is 11.20% and return on invested capital (ROIC) is 7.78%.
Return on Equity (ROE) | 11.20% |
Return on Assets (ROA) | 7.09% |
Return on Capital (ROIC) | 7.78% |
Revenue Per Employee | 5.71M |
Profits Per Employee | 2.27M |
Employee Count | 37 |
Asset Turnover | 0.26 |
Inventory Turnover | 1.80 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -7.59% in the last 52 weeks.
Beta (5Y) | n/a |
52-Week Price Change | -7.59% |
50-Day Moving Average | 54.49 |
200-Day Moving Average | 55.13 |
Relative Strength Index (RSI) | 45.23 |
Average Volume (20 Days) | 12,791 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, G&E Herbal Biotechnology had revenue of TWD 211.15 million and earned 83.82 million in profits. Earnings per share was 1.42.
Revenue | 211.15M |
Gross Profit | 170.74M |
Operating Income | 93.37M |
Pretax Income | 104.80M |
Net Income | 83.82M |
EBITDA | 102.56M |
EBIT | 93.37M |
Earnings Per Share (EPS) | 1.42 |
Balance Sheet
The company has 324.13 million in cash and 2.21 million in debt, giving a net cash position of 321.92 million or 5.78 per share.
Cash & Cash Equivalents | 324.13M |
Total Debt | 2.21M |
Net Cash | 321.92M |
Net Cash Per Share | 5.78 |
Equity (Book Value) | 774.65M |
Book Value Per Share | 13.13 |
Working Capital | 258.41M |
Cash Flow
In the last 12 months, operating cash flow was 133.14 million and capital expenditures -3.84 million, giving a free cash flow of 129.30 million.
Operating Cash Flow | 133.14M |
Capital Expenditures | -3.84M |
Free Cash Flow | 129.30M |
FCF Per Share | 2.32 |
Margins
Gross margin is 80.86%, with operating and profit margins of 44.22% and 39.70%.
Gross Margin | 80.86% |
Operating Margin | 44.22% |
Pretax Margin | 49.64% |
Profit Margin | 39.70% |
EBITDA Margin | 48.57% |
EBIT Margin | 44.22% |
FCF Margin | 61.24% |
Dividends & Yields
This stock pays an annual dividend of 0.54, which amounts to a dividend yield of 1.00%.
Dividend Per Share | 0.54 |
Dividend Yield | 1.00% |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | 1 |
Payout Ratio | n/a |
Buyback Yield | -0.10% |
Shareholder Yield | 0.90% |
Earnings Yield | 2.65% |
FCF Yield | 4.33% |
Stock Splits
The last stock split was on August 20, 2024. It was a forward split with a ratio of 1.06.
Last Split Date | Aug 20, 2024 |
Split Type | Forward |
Split Ratio | 1.06 |